Raltegravir penetration in seminal plasma of healthy volunteers
- PMID: 20308369
- PMCID: PMC2876424
- DOI: 10.1128/AAC.00241-10
Raltegravir penetration in seminal plasma of healthy volunteers
Figures
Similar articles
-
Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers.Antimicrob Agents Chemother. 2011 Sep;55(9):4090-5. doi: 10.1128/AAC.00593-11. Epub 2011 Jul 11. Antimicrob Agents Chemother. 2011. PMID: 21746959 Free PMC article.
-
An examination of drug-drug interactions with raltegravir.HIV Clin. 2010 Spring;22(2):12-15. HIV Clin. 2010. PMID: 20806800 No abstract available.
-
Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.Clin Infect Dis. 2013 Jan;56(2):300-6. doi: 10.1093/cid/cis824. Epub 2012 Sep 21. Clin Infect Dis. 2013. PMID: 23001704 Clinical Trial.
-
Raltegravir, an HIV-1 integrase inhibitor for HIV infection.Curr Opin Investig Drugs. 2008 Aug;9(8):885-98. Curr Opin Investig Drugs. 2008. PMID: 18666037 Review.
-
Raltegravir: in treatment-naive patients with HIV-1 infection.Drugs. 2010 Mar 26;70(5):631-42. doi: 10.2165/11204590-000000000-00000. Drugs. 2010. PMID: 20329808 Review.
Cited by
-
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Clin Pharmacokinet. 2014 Jul;53(7):611-24. doi: 10.1007/s40262-014-0148-z. Clin Pharmacokinet. 2014. PMID: 24859035 Free PMC article. Review.
-
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21. J Antimicrob Chemother. 2016. PMID: 27002074 Free PMC article.
-
Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.J Virol. 2015 Jun;89(11):5772-87. doi: 10.1128/JVI.03628-14. Epub 2015 Apr 1. J Virol. 2015. PMID: 25833047 Free PMC article.
-
HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.PLoS One. 2012;7(8):e43086. doi: 10.1371/journal.pone.0043086. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912795 Free PMC article.
-
Current perspectives in HIV post-exposure prophylaxis.HIV AIDS (Auckl). 2014 Oct 24;6:147-58. doi: 10.2147/HIV.S46585. eCollection 2014. HIV AIDS (Auckl). 2014. PMID: 25368534 Free PMC article. Review.
References
-
- Barau, C., C. Delaugerre, J. Braun, N. de Castro, V. Furlan, I. Charreau, L. Gérard, C. Lascoux-Combe, J. M. Molina, and A. M. Taburet. 2010. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob. Agents Chemother. 54:937-939. - PMC - PubMed
-
- Chan, D. J. 2005. Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr. HIV Res. 3:207-222. - PubMed
-
- D'Avolio, A., L. Baietto, M. Siccardi, M. Sciandra, M. Simiele, V. Oddone, S. Bonora, and G. Di Perri. 2008. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 30:662-669. - PubMed
-
- Jones, A. E., J. A. Talameh, K. B. Patterson, N. L. Rezk, H. A. Prince, and A. D. M. Kashuba. 2009. First-dose and steady-state pharmacokinetics of raltegravir in the genital tract of HIV negative women, abstr. O-06. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther., Amsterdam, Netherlands, 15 April to 1 May 2009.
-
- Kalichman, S. C., G. Di Berto, and L. Eaton. 2008. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex. Transm. Dis. 35:55-60. - PubMed